Sotorasib + Panitumumab for Cancer

This trial tests two treatments, sotorasib and panitumumab, to assess their safety and tolerability in cancer patients already benefiting from sotorasib in another study. Participants will receive either sotorasib alone or in combination with panitumumab to determine the most effective approach. This trial may suit those currently receiving sotorasib in an Amgen study and still experiencing benefits. As a Phase 2 trial, it measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important research.

The trial does not specify if you need to stop taking your current medications. However, you must be currently receiving sotorasib treatment, either alone or with other therapies, as part of an Amgen-sponsored trial.

Research has shown that sotorasib, when used alone, is generally well-tolerated. Common side effects include diarrhea, muscle pain, nausea, tiredness, liver problems, and cough. About 37% of patients needed a dose adjustment due to side effects, and 25% had to discontinue use.

When combined with panitumumab, skin issues such as rashes and dry skin are common, affecting 94% of patients. Other frequent side effects include diarrhea, mouth sores, and fatigue. Despite these side effects, the combination of sotorasib and panitumumab is considered to have an acceptable safety profile, even for patients with extensive prior treatments.

Researchers are excited about the combination of Sotorasib and Panitumumab for cancer treatment because it targets cancer cells in a new way. Sotorasib works by specifically inhibiting a mutated protein called KRAS G12C, which is often found in certain cancers, providing a more precise approach compared to traditional chemotherapy. When used alongside Panitumumab, an antibody that targets the epidermal growth factor receptor (EGFR) on cancer cells, the combination can potentially block multiple pathways that cancer cells use to grow. This dual-targeted approach could lead to more effective treatment outcomes and fewer side effects than standard therapies.

Research has shown that sotorasib, a treatment for cancers with the KRAS G12C mutation, yields promising results. Studies report that patients live for a median of 12.5 months and experience significant tumor shrinkage. In this trial, participants in Arm A will receive sotorasib alone, while Arm B will test the combination of sotorasib with panitumumab. Evidence suggests that this combination can extend the time patients live without their cancer worsening to 5.6 months. Additionally, this combination tends to improve patients' well-being during treatment. Both treatments have demonstrated effectiveness, offering hope for better cancer control.⁶⁷⁸⁹¹⁰